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Abstract 
 
Introduction Factor XIII (FXIII) has an important role in the control of bleeding through 
fibrin cross-linking. While many physiological factors affect plasma FXIII level, the effect of 
the menstrual cycle is not fully understood.  
Aim: To examine changes in plasma FXIII activity during the normal menstrual cycle and to 
assess correlation between FXIII activity during the menstrual phase and menstrual blood 
loss.  
Methods: In this longitudinal study, a total of 32 healthy normal women of reproductive age 
were recruited. Menstrual blood loss was measured using the pictorial blood-assessment chart 
(PBAC). A bleeding score questionnaire was also completed. Blood samples were taken 
during the menstrual, proliferative, periovulatory, secretory , and premenstrual phase for the 
assessment of FXIII level using a quantitative ammonia release assay. 
Results: The mean±SD FXIII level was lowest during menstrual  and periovulatory phases 
(114 ± 23 and 114 ± 21 IU/dL respectively). The mean FXIII level during the secretory and 
premenstrual phases were higher than the menstrual phase (p=0.036). The secretory mean 
FXIII level was also significantly higher compared to the periovulatory phase (p=0.02). There 
was no significant correlation between FXIII level during the menstrual phase and age 
(p=0.53) or PBAC score (p=0.53). There were no significant differences in FXIII level during 
the menstrual phase between women with PBAC score of at least 100 (n=14; mean 116 
IU/dL) and women with PBAC scores less than 100 (n=18; mean 113 IU/dL).  There was no 
correlation between FXIII level and bleeding scores. 
Conclusion: FXIII activity was lower during menstrual and periovulatory phase of the cycle. 
However, the small difference between mean values (8 IU/dL) would be unlikely to have a 
significant impact on diagnosis of FXIII deficiency and clinical management.  
Keywords: Coagulation Factor XIII, Menstrual cycle, Menorrhagia, Ovulation.  
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Introduction 
A wide variation has been reported in the levels of coagulation factors in normal individuals 
and patients affected with bleeding disorders. Different physiological and pathological factors 
have been shown to result in such variation, including: age, sex, blood group, smoking status, 
stress and physical exercise[1,2]. In women, sex hormones also affect the level of coagulation 
factors. This has been demonstrated by the presence of cyclical changes in some coagulation 
factors during the menstrual cycle and by the effects of hormonal contraception and hormone 
replacement therapy [3].  
The effect of the changes of female sex hormones on coagulation factor levels during the 
menstrual cycle may have important clinical implications for the diagnosis and management 
of women with bleeding disorders [3,4]. However, for most coagulation factors, these 
changes have been assessed in a small number of studies with conflicting results, the majority 
having only a small number of women [5]. 
In a cross-sectional study of 123 women, a strong cyclical variation was shown for von 
Willebrand factor (VWF) antigen and activity levels as well as fibrinogen level during the 
menstrual cycle [4]. These cyclical variations were dampened for VWF and completely 
disappeared for fibrinogen with the use of combined hormonal contraceptives [4]. In the same 
study, factor XI showed no variation during the menstrual cycle, but factor XIII (FXIII) was 
not assessed . On the other hand, no difference in VWF was seen during menstrual, follicular 
and luteal phases in a cross-sectional study with no association between the level of estradiol, 
or progesterone and VWF, or factor VIII [6].  
FXIII may have an important role during the menstrual phase of the cycle, in the process of 
healing the endometrium and controlling the menstrual blood loss through fibrin cross-
linking, thus improving the mechanical strength, rigidity and elasticity of the clot to prevent it 
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from being degraded through fibrinolysis [7].  However, the effect of the menstrual cycle on 
FXIII levels is not fully understood and it is not clear whether endometrial healing leads to an 
increase in FXIII consumption, thus altering the plasma level. Variations in FXIII level 
during the menstrual cycle, if present, would need to be considered when performing 
screening tests for FXIII deficiency.  
The aim of this study was to examine possible changes in plasma FXIII activity during the 
normal menstrual cycle and to assess any association between level of FXIII and  menstrual 
bleeding. 
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Materials and Methods 
Study design:   
This was a longitudinal study of 32 women of reproductive age. Demographic and clinical 
data was collected (including; age, ethnicity, previous number of pregnancies and 
miscarriages, body mass index (BMI), and smoking status) through an interview with the 
women. 
Women were recruited from hospital staff through leaflet and poster invitations at Royal Free 
Hospital NHS Foundation Trust in London, UK as well as the Medical Thrombosis and 
Hemophilia treatment Center in Duisburg, Germany, from January to October 2012. The 
study was approved by the hospital ethical committees and informed consent was obtained 
from participating women. Women were included in the study if they had a regular menstrual 
cycle of 26-35 days duration, and were not using hormonal contraception, including Mirena® 
IUS (levonorgestrel-releasing intrauterine system), and were not using non-steroidal anti-
inflammatory drugs. Exclusion criteria also included personal or family history of bleeding 
tendency or thrombo-embolism.  
Menstrual blood loss was measured using the pictorial blood-assessment chart (PBAC) [8]. 
The women were given oral and written instructions on the use of PBAC and were asked to 
complete the chart during the period of blood sample collection. Women were required to 
document the number of sanitary pads and/or tampons used each day (24 hour) based on the 
degree of saturation of the pads/tampons, they were also asked to record the number and size 
of blood clots if present.  The completed PBAC sheets were collected at the end of the 
menstrual period and the total numerical score were calculated by a single gynaecologist 
(LS). The total score was calculated by adding up the pad/tampons counts obtained from each 
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day of the period.  The scores assigned for tampons were ‘1’ for each lightly stained tampon, 
‘5’ if moderately stained and ‘10’ if it was completely saturated with blood. The towels were 
given ascending scores of ‘1’, ‘5’ and ‘20’.  Small and large clots scored ‘1’ and ‘5’, 
respectively PBAC score ≥ 100 were considered a heavy menstrual bleeding [8].  
 A bleeding questionnaire was also completed and the bleeding score (SH, RAK) was 
calculated based on specific symptoms; these included epistaxis, cutaneous symptoms, 
bleeding from minor wounds, muscle haematomas, haemarthrosis, oral cavity bleeding, 
gastrointestinal bleeding, bleeding after tooth extraction, bleeding after surgery, postpartum 
haemorrhage, and menorrhagia. The severity of each symptom was subsequently 
summarised, using a bleeding questionare system ranging from ‘-1’ representing absence of 
bleeding despite haemostatic challenge, ‘0’ representing complete absence of bleeding 
symptoms, ‘1’ given when woman reported presence of bleeding, ‘2’ if the bleeding 
symptoms required evaluation by a physician but no active intervention was needed, ‘3’ if 
bleeding required some kind of intervention by physician, and ‘4’ if blood transfusion or 
surgery was required to control the bleeding. A bleeding score value below ‘3’ is considered 
normal [9].  
Laboratory methods: 
Blood samples were taken  five times during one menstrual cycle as follows: menstrual phase 
(day 1-5), proliferative phase (day 6-11), periovulatory phase (day 12-17), secretory phase 
(days 18-23), and premenstrual phase (day 24-29).  
After obtaining written informed consent, blood samples were obtained between 11:00 a.m. 
and 2:00 p.m. Venous blood samples were collected by clean venepuncture, with minimal 
stasis, into citrate (0.105mol L-1) VacutainersTM (BD Diagnostics, Oxford, UK), with a ratio 
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of one part anticoagulant to 9 parts whole blood. Within one hour of collection platelet poor 
plasma (PPP) was prepared by double centrifugation at ambient temperature (2000g for 10 
minutes) and aliquots of PPP were frozen to -80ºC. On the day of assay samples were thawed 
to 37ºC and mixed. 
Factor XIII activity was determined  using a chromogenic ammonia release assay 
(Berichrom® FXIII assay; Siemens Healthcare Diagnostics, Marburg, Germany) performed 
on a CS-5100 coagulation analyser (Sysmex UK Ltd, Milton Keynes, UK). In this assay, 
FXIII is converted to its active form, FXIIIa, by the action of thrombin in the presence of 
calcium ions. Activated FXIIIa cross-links a specific peptide substrate to glycine ethyl ester, 
thereby releasing ammonia, which is determined in a glutamate dehydrogenase catalysed 
NADH-dependent reaction. The consumption of NADH is measured spectrophotometrically 
by the decreased absorbance at 340 nm [10]. FXIII potencies were calculated relative to 
Standard Human Plasma (SHP, Siemens Healthcare Diagnostics). The manufacturer’s stated 
normal reference range was 70-140 IU/dL. The coefficient of variation at a FXIII level of 87 
IU/dL was 2%. All samples were assayed in a single analytical run, thereby removing the 
effect of inter-assay variation. 
Statistical method: 
Continuous data were presented as mean ± standard deviation (SD). Paired sample t-test was 
used to measure the mean difference and 95% confidence interval (CI) of FXIII activity in 
different phases of the menstrual cycle. Comparison of FXIII changes in relation to PBAC 
score and body mass index (BMI) was performed using an unpaired t-test (p ≤ 0.05 was 
considered statistically significant). The statistical package for social sciences, version 20 
(SPSS, Chicago, USA) was used. 
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Results 
The demographics of 32 women included in this study are illustrated in Table 1. There were 
24 women recruited from Royal Free Hospital in UK and eight women from Medical 
Thrombosis and Hemophilia treatment Center in Germany. All women included in the study 
were non-smokers. Only eight women had a previous history of pregnancy with a total of 20 
pregnancies; four of them resulted in miscarriage. No woman had more than one miscarriage.  
In total, 153 blood samples were collected from the women. Figure 1 shows the distribution 
of FXIII activity during each phase of the menstrual cycle. The mean±SD FXIII level was at 
its lowest at the menstrual (114 ± 23 IU/dL) and the periovulatory (114 ± 21 IU/dL) phases of 
the cycle (Table 2). The FXIII level was significantly higher during the secretory (mean 
difference 8.0 IU/dL, 95% CI 15.5-0.57, p=0.036) and premenstrual (mean difference 8.61 
IU/dL, 95% CI 16.6-0.59, p=0.036) compared withthe menstrual phase. When compared to 
the periovulatory phase, the mean FXIII level was also higher in the secretory (mean 
difference 7.78 IU/dL, 95% CI 1.3-14.2), proliferative (mean difference 5.3 IU/dL, 95% CI 
1.3-12) and premenstrual (mean difference 9.8 IU/dL, 95% CI -0.01-19.7) phases of the 
cycle. No study participants showed FXIII levels below the normal range (70–140 IU/dL). 
The median PBAC score was 92, ranging from 12 to 920. There was no significant 
correlation between FXIII activity during the menstrual phase and age (r=0.03; p=0.85) or 
PBAC score (r=0.11; p=0.53), using Spearman’s correlation coefficient. Among the 14 
women with PBAC score of at least 100, the mean FXIII activity during the menstrual phase 
of the cycle was similar to women with PBAC score less than 100 (116 ± 19 vs. 113 ± 26 
IU/dL, p=0.72). Bleeding score was ‘-1’ in seven (22%) women, ‘0’ in 22 (68%) women, ‘1’ 
in one (4%), and ‘3’ in two (6%) women. Among the three women with bleeding symptoms, 
9 
 
FXIII activities during menstrual phase of the cycle were 180 IU/dL , 164 IU/dLfor two 
women with bleeding score “3”, and 118 IU/dLfor one woman with bleeding score ‘1’. 
To study the effect of obesity on the cyclic change of FXIII activity, 24 women were divided 
into those with BMI of 25 kg/m2 or less (n=13) and more than 25 kg/m2 (n=11). No 
significant difference was observed in FXIII activity at different phases of the menstrual 
cycle between the two groups, including the menstrual phase of the cycle. The mean FXIII 
activity was the lowest during the menstrual phase of the cycle in women with BMI of 25 
kg/m2 or less and more than 25 kg/m2 (111 ± 25 vs. 119 ± 27 IU/dL, p= 0.46).  
Discussion 
In this study, the mean FXIII activity was significantly higher toward the last two weeks of 
the cycle compared to the menstrual phase. FXIII level was at its lowest during the menstrual 
and ovulatory phase. A significant decrease in FXIII level during the periovulatory phase of 
the cycle has been previously reported in a small study including 10 women. However, FXIII 
level was not assessed during menstrual phase in the study [11]. The hormonal levels 
(estrogen and progesterone) are at their baseline during these phases of the menstrual cycle 
with a peak of estrogen in the follicular phase and peak estrogen and progesterone during the 
luteal phase. These hormonal fluctuations may explain FXIII variations during the cycle. 
However, there could also be increased consumption of this factor due to its role in healing, 
angiogenesis and fibrin stabilisation during the menstrual and ovulatory phase of the cycle. 
Activated FXIII induces a severe reduction in the thrombospondin-1 (TSP-1) mRNA and 
reduces TSP-1 levels in the conditioned medium. TSP-1 acts as an angiogenesis inhibitor by 
preventing endothelial cell proliferation and migration, as well as inducing apoptosis [12]. 
Further mediators for FXIII pro-angiogenic effects involve upregulation of certain 
transcription factors, and tyrosine phosphorylation and activation of vascular endothelial 
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growth factor receptor-2 [13,14]. This proangiogenic function of FXIII might be important in 
endometrial healing, regeneration and vascular reproliferation following endometrial layer 
shedding during menstrual cycle as well as ovarian surface at site of follicular rupture during 
ovulation.   
We did not find any correlation between FXIII level during menstrual phase and menstrual 
bleeding. There was no significant difference in FXIII activity in women with heavy 
menstrual bleeding (PBAC score equal or more than 100) compared to those with normal 
menstrual bleeding. However, it is important to note that the PBAC was used in this study to 
measure menstrual blood loss and this is a simple tool that only allows a semi- objective 
assessment of menstrual blood loss [15]. The PBAC was chosen rather than a more objective 
assessment tool, like alkaline hematin, because it is more practical and less expensive. In 
addition, the number of women in the study is small. Studies with a large number of women 
are required to determine the correlation between menstrual blood loss and  FXIII level. 
In our study, bleeding symptoms were reported in only three women with a score of ‘1’ and 
‘3’ in one and two women respectively. Bleeding symptoms can be reported by patients in the 
absence of any congenital or aquired bleeding disorders, with at least one haemorrhagic 
symptom being reported in up to 25% of normal subjects [16]. There were no abnormal FXIII 
levels observed in those women with bleeding symptoms. However, the number of women 
with bleeding symptoms was very small in this study.  Even in patients with FXIII 
deficiency, there is no single bleeding symptom sufficiently specific or sensitive to identify 
patients with FXIII-B-subnit deficiency or those with heterozygous FXIII deficiency, both of 
which are characterised by a milder bleeding tendency.  
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This study showed that there is a trend towards differences in FXIII in various phases of the 
menstrual cycle. FXIII levels were significantly higher during the luteal and premenstrual 
phases and the lowest level was seen during the menstrual and ovulatory phases.  This could 
be due to fluctuations in the hormonal levels. However, the difference was small with only 8 
IU/dL  difference between the highest and the lowest mean FXIII level during the cycle. 
Based on our study this small change in FXIII level in different phases of the menstrual cycle 
is unlikely to influence the diagnosis of FXIII deficiency. Therefore, there should be no 
restrictions on performing FXIII assays based on the phase of the menstrual cycle. Whether 
this small variation in FXIII levels reflects the normal variations that can occur with repeated 
measurement of FXIII is a possibility. This can only be determined by further studies 
assessing this variation in comparison with men and postmenopausal women. The decrease in 
the level of FXIII seen in the menstrual and ovulatory phases in our study may also reflect the 
role of FXIII in tissue regeneration, healing and haemostasis during these phases of the cycle. 
This finding warrants further studies in assessing the role of FXIII in women with normal and 
abmormal menstrual and ovulatory bleeding.  
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Figure Legend:  
Figure 1 Distribution of FXIII activity (mean ±SD) during each phase of the menstrual 
cycle 
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Table 1 Demographics of 32 women with normal menstrual cycle included for this study 
Variables Outcome 
Country of origin, No. (%)  
Caucasian  16 ( 50) 
Asian 10 (31) 
Afro-Caribbean  6 (19) 
Women with previous miscarriage No. (%)  
Yes 4 (12,5) 
No 28 (87.5) 
Previous pregnancies No. (%)  
None 24 (76) 
1 2 (6) 
2 2 (6) 
3 2 (6) 
4 2 (6) 
BMI (Kg/m2); Mean ±SD (range) 25 ± 4.5 (19 to 36.5) 
Age (years); Mean ±SD (range) 28.8 ± 8 (18 to 42) 
Height (cm); Mean ±SD 162 ± 7 
Weight (kg); Mean ±SD 66 ±14 
 
SD= standard deviation 
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Table 2 FXIII level (IU/dL) at different phases of menstrual cycle in 32 healthy women 
and in comparison to the menstrual phase. 
 Week 0 
(Menstrual) 
Week 1 
(proliferative) 
Week 2 
(periovulatory) 
Week 3 
(Secretory) 
Week 4 
(premenstrual) 
Number of samples 32 32 32 31 22 
Mean 114 119 114 120 122 
SD 23 26 21 22 27 
Lower limit 80 72 77 78 73 
Upper limit 180 200 179 171 185 
p-value* - 0.058 0.997 0.036 0.036 
 
* Paired t-test comparing mean FXIII activity of menstural phase to other phases of the cycle. 
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Figure 1 Distribution of FXIII activity during each phase of the menstrual cycle; central 
horizontal lines show mean FXIII activity and top and bottom lines show standard 
deviation of the mean.  
 
